RGD Reference Report - A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.

Authors: Takami, A  Espinoza, JL  Onizuka, M  Ishiyama, K  Kawase, T  Kanda, Y  Sao, H  Akiyama, H  Miyamura, K  Okamoto, S  Inoue, M  Ohtake, S  Fukuda, T  Morishima, Y  Kodera, Y  Nakao, S   
Citation: Takami A, etal., Bone Marrow Transplant. 2011 Feb;46(2):238-43. doi: 10.1038/bmt.2010.88. Epub 2010 Apr 19.
RGD ID: 11040884
Pubmed: PMID:20400988   (View Abstract at PubMed)
DOI: DOI:10.1038/bmt.2010.88   (Journal Full-text)

Fcgamma receptor type IIIA (FCGR3A) has a functional single-nucleotide polymorphism (rs396991), at which a G-to T-point mutation results in an amino acid substitution at position 158 (valine to phenylalanine; V158F). This study examined the effect of the FCGR3A polymorphism in donors and recipients on the clinical outcomes in unrelated HLA fully matched myeloablative BMT. The FCGR3A-V158F genotype was retrospectively analyzed in a total of 99 recipients with myeloid malignancies, and their unrelated donors. The presence of the 158V genotype in recipients showed a statistically better OS (adjusted hazard ratio (HR) 0.49; 95% confidence interval (CI) 0.26-0.93; P=0.03) and TRM (HR 0.30; 95% CI 0.14-0.67; P=0.003) without significant influence on the relapse rate. The recipient 158V genotype was also associated with a significantly reduced risk of chronic GVHD (HR 0.45; 95% CI 0.20-0.99; P=0.049) and a trend toward a reduced risk of grade II-IV acute GVHD (HR 0.55; 95% CI 0.27-1.10; P=0.09), leading to a significantly reduced GVHD-related mortality (HR 0.22; 95% CI 0.06-0.77; P=0.02). The donor FCGR3A polymorphism did not have any effect on the transplant outcomes. These results suggest an association between the recipient FCGR3A genotype and the clinical outcomes after BMT.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
FCGR3AHumangraft-versus-host disease  IAGP DNA:polymorphism:cds:p. V158F(rs396991)(human)RGD 
Fcgr3aRatgraft-versus-host disease  ISOFCGR3A (Homo sapiens)DNA:polymorphism:cds:p. V158F(rs396991)(human)RGD 
Fcgr4Mousegraft-versus-host disease  ISOFCGR3A (Homo sapiens)DNA:polymorphism:cds:p. V158F(rs396991)(human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Fcgr3a  (Fc gamma receptor 3A)

Genes (Mus musculus)
Fcgr4  (Fc receptor, IgG, low affinity IV)

Genes (Homo sapiens)
FCGR3A  (Fc gamma receptor IIIa)

Objects referenced in this article
Gene FCGR2A Fc gamma receptor IIa Homo sapiens
Gene Fcgr3 Fc receptor, IgG, low affinity III Mus musculus
Gene Fcgr2a Fc gamma receptor 2A Rattus norvegicus

Additional Information